IXJ
ThematiciShares Global Healthcare ETF
About this ETF
The Fund seeks to achieve its objective by tracking the performance of the S&P Global 1200 Health Care Sector Net TR IndexTM (AUD).
IssueriShares
Management fee (MER)0.41% p.a.
Inception date11 Mar 2009
BenchmarkS&P Global 1200 Healthcare Sector TR AUD
Scout Score
65/100
Ranked #11 of 50 in ThematicAn independent score calculated by ETF Scout across 7 real-data factors (cost, diversification, tracking, liquidity, fund strength, performance, income), ranked against other funds in the same category.
Cost82
Diversification6
Tracking71
Liquidity77
Fund Strength95
Performance56
Income37
Strengths
- Large, established fund — $1.5B in assets, bigger than 95% of Thematic funds.
- Low fee — 0.41% p.a., cheaper than 82% of Thematic funds.
- Highly liquid — 0.04% bid/ask spread, better than 77% of Thematic peers.
Weaknesses
- Concentrated holdings — top holdings make up 144.6% of the fund, more concentrated than 94% of Thematic peers.
Performance (as of 5 Jan 2026)
Total returns, net of fees. Periods longer than 1 year are annualised.
1 Month+9.09%
3 Months+12.18%
YTD+10.47%
1 Year+16.49%
3 Years (p.a.)+9.92%
5 Years (p.a.)+7.88%
Price history
Cumulative return over the selected period, indexed to 0% at the start of the range.
Geographic exposure (as at 4 Jan 2026)
Country (where the company is based).
United States99.96%
Australia0.04%
Sector breakdown (as at 4 Jan 2026)
How your portfolio's holdings are spread across GICS sectors.
Financials
99.97%
Top holdings (as of 3 Jan 2026)
The fund's largest individual holdings, ranked by portfolio weight.
- 1.Ishares Global Healthcare Etf Trus99.82%
- 2.
Eli Lilly11.60%
- 3.
Johnson & Johnson6.60%
- 4.
Abbvie5.20%
- 5.
Unitedhealth Group4.11%
- 6.
Merck & Co Inc4.03%
- 7.Roche Ps Par AG3.79%
- 8.
Novartis AG3.32%
- 9.
Astrazeneca plc3.24%
- 10.
Thermo Fisher Scientific2.92%
- 11.
Amgen Inc2.82%
- 12.
Gilead Sciences2.35%
- 13.
Abbott Laboratories2.14%
- 14.
Pfizer1.93%
- 15.
Intuitive Surgical1.76%
- 16.
Danaher1.63%
- 17.
Vertex Pharmaceuticals1.52%
- 18.Novo Nordisk Class B1.46%
- 19.Bristol Myers Squibb1.43%
- 20.
Medtronic plc1.37%